We report two patients with normocomplementaemic urticarial vasculitis with impressive response to omalizumab. This contrasts recent reports on hypocomplementaemic urticarial vasculitis syndrome, highlighting the need for clinical trials of omalizumab in normocomplementaemic urticarial vasculitis.
CITATION STYLE
De Brito, M., Huebner, G., Murrell, D., Bullpitt, P., & Hartmann, K. (2018). Normocomplementaemic urticarial vasculitis: Effective treatment with omalizumab. Clinical and Translational Allergy, 8(1). https://doi.org/10.1186/s13601-018-0222-y
Mendeley helps you to discover research relevant for your work.